Kristie L. Kahl | Authors


Following De-Escalated Neoadjuvant T-DM1 in HR+/HER2+ Early Breast Cancer, Biomarkers May Predict Outcomes

September 20, 2021

When comparing de-escalated neoadjuvant ado-trastuzumab emtansine, with or without endocrine therapy, vs trastuzumab plus endocrine therapy baseline tumor immunogenicity may be associated with higher pathologic complete response rates and favorable outcomes in hormone receptor-positive, human epidermal growth factor receptor 2-positive early stage breast cancer.

Post Hoc Analysis Suggests Lenvatinib Therapy May Continue in Patients with Unresectable HCC, Child–Pugh class Liver Function

July 01, 2021

Patients with unresectable hepatocellular carcinoma with Child-Pugh class B liver function experienced a similar tumor size reduction as their Child-Pugh class A counterparts, all treated with lenvatinib, according to a post-hoc analysis of the phase 3 REFLECT study.